Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Jay Chol | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Park, Tai Hwan | - |
dc.contributor.author | Park, Sang-Soon | - |
dc.contributor.author | Cho, Yong-Jin | - |
dc.contributor.author | Park, Jong-Moo | - |
dc.contributor.author | Kang, Kyusik | - |
dc.contributor.author | Lee, Kyung Bok | - |
dc.contributor.author | Lee, Soo-Joo | - |
dc.contributor.author | Ko, Youngchai | - |
dc.contributor.author | Kim, Jae Guk | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Cho, Ki-Hyun | - |
dc.contributor.author | Kim, Joon-Tae | - |
dc.contributor.author | Yu, Kyung-Ho | - |
dc.contributor.author | Lee, Byung-Chul | - |
dc.contributor.author | Oh, Mi-Sun | - |
dc.contributor.author | Cha, Jae-Kwan | - |
dc.contributor.author | Kim, Dae-Hyun | - |
dc.contributor.author | Nah, Hyun-Wook | - |
dc.contributor.author | Kim, Dong-Eog | - |
dc.contributor.author | Ryu, Wi-Sun | - |
dc.contributor.author | Kim, Beom Joon | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.contributor.author | Kim, Wook-Joo | - |
dc.contributor.author | Shin, Dong-Ick | - |
dc.contributor.author | Yeo, Min-Ju | - |
dc.contributor.author | Il Sohn, Sung | - |
dc.contributor.author | Hong, Jeong-Ho | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.date.accessioned | 2021-09-04T13:11:40Z | - |
dc.date.available | 2021-09-04T13:11:40Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 2287-6391 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92660 | - |
dc.description.abstract | Background and Purpose In a recent pooled analysis of randomized clinical trials (RCTs), intravenous tissue plasminogen activator (TPA) improves the outcome in patients aged >= 80 years. However, it is uncertain whether the findings are applicable to clinical practice in Asian populations. Methods From a multicenter stroke registry database of Korea, we identified patients with acute ischemic stroke who were aged >= 80 years. Using multivariable analysis and propensity score (PS)-matched analyses, we assessed the effectiveness and safety of intravenous TPA within 4.5 hours. Results Among 2,334 patients who met the eligible criteria, 236 were treated with intravenous TPA (mean age, 83 +/- 5; median NIHSS, 13 [IQR, 8-17]). At discharge, the TPA group compared to the no-TPA group had a favorable shift on the modified Rankin Scale (mRS) score (multivariable analysis, OR [95% Cl], 1.51 [1.17-1.96], P=0.002; PS-matched analysis, 1.54 [1.17-2.04], P=0.002) and was more likely to achieve mRS 0-1 outcome (multivariable analysis, 2.00 [1.32-3.03], P=0.001; PS-matched analysis, 1.59 [1.04-2.42], P=0.032). TPA treatment was associated with an increased risk of symptomatic intracranial hemorrhage (multivariable analysis, 5.45 [2.80-10.59], P<0.001; PS-matched analysis, 4.52 [2.24-9.13], P<0.001), but did not increase the in-hospital mortality (multivariable analysis, 0.86 [0.50-1.48], P=0.58; PS-matched analysis, 0.88 [0.52-1.47], P=0.61). Conclusions In the setting of clinical practice, intravenous TPA within 4.5 hours improved the functional outcome despite an increased risk of symptomatic intracranial hemorrhage in very elderly Korean patients. The findings, consistent with those from pooled analysis of RCTs, strongly support the use of TPA for this population. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN STROKE SOC | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | THROMBOLYTIC THERAPY | - |
dc.subject | REGISTRY | - |
dc.subject | ALTEPLASE | - |
dc.subject | POPULATION | - |
dc.subject | SURVIVAL | - |
dc.subject | ECASS | - |
dc.subject | RISK | - |
dc.title | Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.5853/jos.2015.17.3.327 | - |
dc.identifier.scopusid | 2-s2.0-84942911263 | - |
dc.identifier.wosid | 000362802100010 | - |
dc.identifier.bibliographicCitation | JOURNAL OF STROKE, v.17, no.3, pp.327 - 335 | - |
dc.relation.isPartOf | JOURNAL OF STROKE | - |
dc.citation.title | JOURNAL OF STROKE | - |
dc.citation.volume | 17 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 327 | - |
dc.citation.endPage | 335 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | THROMBOLYTIC THERAPY | - |
dc.subject.keywordPlus | REGISTRY | - |
dc.subject.keywordPlus | ALTEPLASE | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | ECASS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordAuthor | Ischemic stroke | - |
dc.subject.keywordAuthor | Thrombolytic therapy | - |
dc.subject.keywordAuthor | Outcome assessment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.